Allogene Therapeutics ALLO Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's additional paid-in capital?
- Allogene Therapeutics (ALLO) reported additional paid-in capital of $2.33B in Q1 2026.
- How has Allogene Therapeutics's additional paid-in capital changed year-over-year?
- Allogene Therapeutics's additional paid-in capital increased by 3.0% year-over-year, from $2.26B to $2.33B.
- What is the long-term trend for Allogene Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Allogene Therapeutics's additional paid-in capital has grown at a 5.9% compound annual growth rate (CAGR), from $1.73B to $2.3B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.